AACR annual meeting 2026
6 April 2026
Lyon, France, April 17th, 2026 – OREGA Biotech, the biotech company committed to the discovery of novel immuno-oncology targets for cancer immunotherapy, reported today that the AACR 2026 abstract reporting interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durvalumab) and platinum-based chemotherapy in patients with resectable early stage non-small cell lung cancer (NSCLC) has been published.
Summary of the abstract: Perioperative PD-(L)1 inhibitors combined with chemotherapy are now standard for resectable early-stage NSCLC, but further improvements in pathological complete response (pCR) and survival are still needed. IPH5201, an anti-CD39 antibody, aims to enhance antitumor immunity by reducing immunosuppressive adenosine and increasing ATP levels. In the Phase 2 MATISSE study, IPH5201 was added to durvalumab and chemotherapy in patients with stage II–IIIA NSCLC. Among 40 patients, the treatment showed a favorable safety profile and achieved a pCR rate of 27.5% (all), rising to 35.7% in PD-L1 ≥1% and 50% in PD-L1 ≥50% patients, comparing favorably with the 17.2%, 21.2% and 27.5% reported for durvalumab + chemo in the AEGEAN study (Heymach, 2023). Biomarker analyses confirmed CD39 target engagement and suggested a link between CD39+ tumor cell density and response. These results compare favorably to prior standards and support the continuation of the study with the recruitment of PD-L1≥1% pts.
Presentation details:
Session CTPL04 – Advances in Immunotherapy
CT231 – Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC.
Session Date/Time: April 21, 2026, 10:45 AM – 11:00 AM Hall H – Ground Level – Convention Center
Presenter: Pr. Fabrice Barlesi, CEO of Institut Gustave Roussy
About IPH5201 antibody
IPH5201 is a humanized CD39 blocking antibody codeveloped by Innate Pharma and AstraZeneca (AZ).
OREGA Biotech entered into an exclusive and worldwide License Agreement with Innate Pharma in 2016. The lead antibody (IPH5201) has been further partnered with AstraZeneca in 2018. AstraZeneca conducted a multicenter, open-label, dose-escalation Phase 1 trial in advanced solid tumors (NCT04261075) with IPH5201 alone or in combination with durvalumab (anti PD-L1 antibody).
About NCT05742607 clinical trial
MATISSE is a Phase 2 multicenter single-arm study (NCT05742607) evaluating neoadjuvant and adjuvant treatment with IPH5201 in combination with durvalumab (anti-PD-L1, AZ) and chemotherapy in treatment-naïve patients with resectable early-stage non-small cell lung cancer (NSCLC). The primary objectives of the study are to assess antitumor activity of neoadjuvant treatment based on pathological complete response (pCR) and safety. More information on the Phase 2 clinical trial is accessible online.
About OREGA Biotech
OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. Our in vivo screening platform aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Incepted in 2010, OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our business strategy is to establish preclinical proof of concept with new targets prior to enter into early-stage partnership or license agreements with larger biotech or pharmaceutical companies. The company is managed by Jeremy Bastid, CEO and Gilles Alberici, President.
Contact
Jeremy Bastid, Chief Executive Officer
Tel.: +33 (0)4 37 49 87 20
Email : jeremy.bastid@orega-biotech.com
